This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients (HOPEMD)

This study has been completed.
Information provided by (Responsible Party):
Bioblast Pharma Ltd. Identifier:
First received: December 8, 2013
Last updated: July 21, 2017
Last verified: July 2017
The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.

Condition Intervention Phase
Oculopharyngeal Muscular Dystrophy Drug: Cabaletta Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients

Resource links provided by NLM:

Further study details as provided by Bioblast Pharma Ltd.:

Primary Outcome Measures:
  • Safety Lab Evaluations [ Time Frame: 28 weeks ]
    Change from baseline in safety labs including hematology, coagulation, chemistry, renal function, and liver function tests.

Secondary Outcome Measures:
  • Drinking Test Score [ Time Frame: 28 weeks ]
    Change from baseline in ice water drinking time, in seconds

  • Videofluoroscopy (VFS) Score [ Time Frame: 28 Weeks ]
    Summary of Penetration aspiration score results assessed by VFS over time, change from baseline

  • SWAL-QOL [ Time Frame: 28 weeks ]
    Summary of Quality of Life in Swallowing Disorders total symptom score results over time, change from baseline

Enrollment: 25
Study Start Date: February 2014
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cabaletta 30gr.
weekly IV of Cabaletta 30gr.
Drug: Cabaletta


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females
  • 18 - 80 years (inclusive) of age
  • Clinically and genetically diagnosed as OPMD
  • Moderate dysphagia (abnormal drinking test at screening and on the first dosing day, before drug administration)
  • Patients who provide written informed consent to participate in the study
  • Body Mass Index (BMI) <30 kg/m2

Exclusion Criteria:

  • Diabetes mellitus type 1 or 2
  • Other major diseases, e.g.: renal failure (creatinine clearance <60ml/min), liver failure and chronic liver diseases (e.g. hepatitis B or C) , HIV carriers, tuberculosis, SLE, rheumatoid polyarthritis, sarcoidosis, collagenosis
  • Uncontrolled heart disease , CHF,
  • Other neuromuscular diseases
  • Other disorders associated with esophageal dysphagia: e.g. severe gastroesophageal reflux (GERD), esophageal stricture due to mechanical or chemical trauma, infection (e.g. esophageal moniliasis), drug-induced dysphagia (e.g. bisphosphonates), esophageal rings and webs, spastic motility disorders of the esophagus.
  • History of malignancy (except non-invasive skin malignancy)
  • History of neck irradiation
  • Pregnant or currently lactating women
  • Obesity (BMI≥ 30) and associated morbidity
  • Prior pharyngeal myotomy
  • Weight loss of more than 10% in the last 12 months.
  • Known hypersensitivity to any ingredients in the injection
  • Patient receiving anticoagulant treatment (e.g. warfarin)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02015481

United States, California
Los Angeles, California, United States, 90095
Tahseen Mozaffar
Orange, California, United States, 92868
Canada, Quebec
Montreal Neurological Institute, McGill University
Montreal, Quebec, Canada, H3A 2B4
Hadassah medical center
Jerusalem, Israel, 91120
Sponsors and Collaborators
Bioblast Pharma Ltd.
Principal Investigator: Yoseph Caraco, M.D Hadassah Medical Center
Principal Investigator: Bernard Brais, MD Montreal Neurological Institute, McGill University
  More Information

Responsible Party: Bioblast Pharma Ltd. Identifier: NCT02015481     History of Changes
Other Study ID Numbers: BBCO-001
Study First Received: December 8, 2013
Results First Received: July 21, 2017
Last Updated: July 21, 2017

Keywords provided by Bioblast Pharma Ltd.:
Case control, safety, tolerability, efficacy.

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Oculopharyngeal
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn processed this record on September 19, 2017